CONSOLIDATED CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2019	Sep. 30, 2018
CURRENT ASSETS
Cash	$ 7,855	$ 8,019
Accounts Receivable, Related Party	71,186	0
Note Receivable, Related Party	0	4,551
Prepaid Expenses	76	8,259
Accrued Interest Receivable, Related Partry	0	7,672
Prepaid Rent	0	14,270
Total Current Assets	79,117	42,771
Investment Securities, Related Party	19,969	166,247
Total Other Assets	19,969	166,247
TOTAL ASSETS	99,087	209,018
Current Liabilities:
Bank Overdraft	0	203
Accounts payable	92,000	80,567
Notes Payable	88,627	227
Accrued payroll taxes	4,241	4,241
Accrued Interest	525,335	292,094
Accrued Rent	5,000	0
Accrued Payroll	972,158	655,663
Other Accrued Expenses	41,423	41,243
Due to Investor	20,000	20,000
Derivative Liability	7,200,528	6,736,607
Convertible Notes Payable Less unamortized discount	2,051,537	774,666
Unearned Income	0	68,000
Convertible Notes Payable, Related Parties Less unamortized discount	2,056	0
Total Current Liabilities	11,002,904	8,673,511
Long Term Liabilities:
Convertible Notes Payable less unamortized discount	0	656,272
Convertible Notes Payable, Related Parties Less unamortized discount	4,978	906
Total Long Term Liabilities	4,978	657,178
Total Liabilities	11,007,882	9,330,689
STOCKHOLDERS EQUITY (DEFICIT)
Common Stock ($.0001 par value) 500,000,000 shares authorized; 180,315,107 issued and outstanding as of September 30, 2018 and 4,800,000,000 authorized and 600,001,406 shares issued and outstanding September 30, 2019	59,998	18,030
Additional Paid in capital	8,261,993	7,517,888
Contributed Capital	728,658	728,658
Retained Earnings (Deficit)	(19,998,086)	(17,457,044)
Accumulated Other Comprehensive Income	0	52,948
Shareholders Equity Regen Biopharma	(10,908,795)	(9,121,671)
Non Controlling Interest KCL Therapeutics	0	0
Total Stockholders' Equity (Deficit)	(10,908,795)	(9,121,671)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	99,087	209,018
Series A Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	34,838	14,044
Series AA Preferred Stock
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	5	0
Series M Preferred Stock [Member]
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock Value	$ 3,800	$ 3,800